Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response
- DOI
- 10.2147/dddt.s646469
- Published
- 2026-11
- Container
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.2147/dddt.s646469,
title = {Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response},
author = {Jing Wang and Fengjiao Li and Yalin Wang and Xianxian Kong and Weiyan Zhou},
year = {2026},
journal = {Drug Design, Development and Therapy},
doi = {10.2147/dddt.s646469},
url = {https://doi.org/10.2147/dddt.s646469}
}RIS
TY - JOUR TI - Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response AU - Jing Wang AU - Fengjiao Li AU - Yalin Wang AU - Xianxian Kong AU - Weiyan Zhou PY - 2026 JO - Drug Design, Development and Therapy DO - 10.2147/dddt.s646469 UR - https://doi.org/10.2147/dddt.s646469 ER -
APA
Wang, J., Li, F., Wang, Y., Kong, X., & Zhou, W. (2026). Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s646469
Source records
- crossref · retrieved 2026-11-10T07:14:04.375Z